Neuropediatrics 2009; 40(1): 28-31
DOI: 10.1055/s-0029-1231066
Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Treatment of Gastroesophageal Reflux with Nissen Fundoplication and Gastrostomy Tube Insertion in Infantile Pompe's Disease

M. Hirschburger 1 , 6 , A. Hecker 1 , 6 , W. Padberg 1 , B. A. Neubauer 2 , R. Motz 3 , C. Haase 4 , T. Marquardt 5 , A. Hahn 2
  • 1Department of General and Thoracic Surgery, University of Giessen, Giessen, Germany
  • 2Department of Neuropediatrics, University of Giessen, Giessen, Germany
  • 3Department of Pediatric Cardiology, Elisabeth Hospital, Oldenburg, Germany
  • 4Department of Pediatrics, University of Jena, Jena, Germany
  • 5Department of Pediatrics, University of Münster, Münster, Germany
  • 6These authors contributed equally to this work
Further Information

Publication History

received 11.04.2009

accepted 19.06.2009

Publication Date:
28 July 2009 (online)

Abstract

In infantile Pompe's disease, enzyme replacement therapy (ERT) has been shown to reverse cardiomyopathy, improve skeletal muscle strength, and prolong survival. We report on five patients in whom complications related to gastroesophageal reflux (GER) resulted in deterioration of their clinical status despite initial improvement under ERT. Surgical antireflux therapy, performed in four, yielded positive results in two. Three patients experienced severe aspirations related to GER and underwent fundoplication and gastrostomy subsequently. Two did not regain former motor functions and deceased shortly thereafter, while one slowly recuperated and is in a stable state at age 53 months. In a further patient, severe GER prompted fundoplication at age 17 months. No aspirations occurred until the girl deceased probably due to cardiac arrest 20 months later. These cases suggest that infants with Pompe's disease under ERT may benefit from timely performed fundoplication and gastric tube placement.

References

  • 1 Amalfitano A, Bengur R, Morse RP. et al . Recombinant α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.  Genet Med. 2001;  3 132-138
  • 2 Bach JR, Saltstein K, Sinquee D. et al . Long-term survival in Werdnig-Hoffmann disease.  Am J Phys Med Rehabil. 2007;  86 339-345
  • 3 Birnkrant DJ, Pope JF, Martin JE. et al . Treatment of type I spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding.  Pediatr Neurol. 1998;  18 407-410
  • 4 Costi D, van der Walt JH. General anesthesia in an infant with X-linked myotubular myopathy.  Paediatr Anaesth. 2004;  14 964-968
  • 5 Fonkalsrud EW, Ament ME. Gastroesophageal reflux in childhood.  Curr Probl Surg. 1996;  33 1-70
  • 6 Hirschhorn R, Reuser AJJ. Glycogen Storage Disease Type II: Acid α-Glucosidase (acid maltase) deficiency. In: The Metabolic & Molecular Bases of Inherited Disease, 8th edition. 2001 chapter 135
  • 7 Jenkins JA, Facer EK. Anesthetic management of a patient with myotonic dystrophy for a Nissen fundoplication and gastrostomy.  Paediatr Anaesth. 2004;  14 693-696
  • 8 Kampmann C, Wiethoff CM, Wenzel A. et al . Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe.  Heart. 2000;  83 667-672
  • 9 Kawahara H, Okuyama H, Kubota A. et al . Can laparoscopic antireflux surgery improve the quality of life in children with neurologic and neuromuscular handicaps?.  J Ped Surg. 2004;  39 1761-1764
  • 10 Kishnani PS, Nicolino M, Voit T. et al . Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease.  J Pediatr. 2006;  149 89-97
  • 11 Kishnani PS, Steiner RD, Bali D. et al . Pompe disease diagnosis and management guideline.  Genet Med. 2006;  8 267-288
  • 12 Kishnani PS, Wuh-Liang H, Mandel H. et al . A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.  J of Pediatrics. 2006;  148 671-676
  • 13 Kishnani PS, Corzo D, Nicolino M. et al . Recombinant human acid α-glucosidase. Major clinical benefits in infantile-onset Pompe disease.  Neurology. 2007;  68 1-11
  • 14 Klinge L, Straub V, Neudorf U. et al . Safety and efficacy of recombinant alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.  Neuromuscul Disord. 2005;  15 24-31
  • 15 McHoney MC, Corizia L, Eaton S. et al . Laparoscopic surgery in children is associated with an intraoperative hypermetabolic response.  Surg Endosc. 2006;  20 452-457
  • 16 Tovar JA, Luis AL, Encinas JL. et al . Pediatric surgeons and gastroexophageal reflux.  J Pediatr Surg. 2007;  42 277-283
  • 17 Van den Hout H, Reuser AJJ, Vulto AG. et al . Recombinant human α-glucosidase from rabbit milk in Pompe patients.  Lancet. 2000;  356 397-398
  • 18 Van den Hout HM, Hop W, van Diggelen OP. et al . The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.  Pediatrics. 2003;  112 332-340
  • 19 Wang LY, Ross AK, Li JS. et al . Cardiac arrhythmias following anesthesis induction in infantile-onset Pompe disease: a case series.  Paediatr Anaesth. 2007;  17 738-748
  • 20 Yuan N, Wang CH, Trela A. et al . Laparoscopic Nissen fundoplication during gastrostomy tube placement and noninvasive ventilation may improve survival in type I and severe type II spinal muscular atrophy.  J Child Neurol. 2007;  22 727-731

Correspondence

A. HahnMD 

Department of Neuropediatrics

University of Giessen

Feulgenstraße12

35385 Giessen

Germany

Phone: +49/641/994 3481

Fax: +49/641/994 3489

Email: Andreas.Hahn@paediat.med.uni-giessen.de

    >